Serina Therapeutics, Inc. SER
Set alert
1.94 USD +0.05 +2.65%
At close · Oct 30
1.95 +0.01 +0.52%
After hours · Oct 30, 7:23 PM ET
1.69 Day range 2.50
1.28 52-week range 5.00
- YTD
- +1.57%
- 1 year
- -59.50%
- Open
- 1.47
- Prev close
- 1.89
- Mkt cap
- 49.28M
- Vol
- 155.11K
- Avg vol
- 67.75K
- EPS
- -1.87
- P/E
- 0.00
- Div yield
- 0.00%
More statistics
- Low
- 1.69
- High
- 2.50
- Forward P/E
- 0.00
- Beta
- 0.00
- Short ratio
- 1.96
- Inst. own
- 3.37%
- Dividend
- 0.00
- Ex-div date
- 50-d avg
- 5.80
- 200-d avg
- 8.47
- 1y target
- 0.00
3M chart
Signals (17)
| Name | Date | Ago |
|---|---|---|
| SMA: Bullish | Oct 30, 2026 | 2 days ago |
| MACD: Buy Signal | Oct 27, 2026 | 5 days ago |
| RSI: Oversold | Oct 19, 2026 | 1 week ago |
| RSI: Oversold | Oct 14, 2026 | 2 weeks ago |
| SMA: Bearish | Sep 15, 2026 | 1 month ago |
| SMA: Bullish | Sep 14, 2026 | 1 month ago |
| SMA: Bearish | Sep 11, 2026 | 1 month ago |
| SMA: Bearish | Sep 10, 2026 | 1 month ago |
| SMA: Bullish | Sep 9, 2026 | 1 month ago |
| SMA: Bearish | Sep 8, 2026 | 1 month ago |
| SMA: Bullish | Sep 1, 2026 | 2 months ago |
| SMA: Bearish | Aug 31, 2026 | 2 months ago |
| MACD: Sell Signal | Aug 25, 2026 | 2 months ago |
| RSI: Overbought | Aug 10, 2026 | 2 months ago |
| MACD: Buy Signal | Aug 5, 2026 | 2 months ago |
| SMA: Bullish | Aug 3, 2026 | 3 months ago |
| SMA: Bearish | Jul 31, 2026 | 3 months ago |
Key statistics
- Market cap
- 50.72M
- Enterprise value
- 61.58M
- Trailing P/E
- 33.75
- Forward P/E
- 0.00
- PEG ratio
- 0.00
- Price / sales
- 16.07
- Price / book
- 0.00
- EPS (TTM)
- 0.16
- Beta
- 0.00
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Profit margin
- -232.86%
- Revenue (TTM)
- 3.16M
- Revenue growth
- -53.10%
- Free cash flow
- -7.45M
- Total cash
- 3.19M
- Total debt
- 11.47M
- Return on equity
- 0.00%
- Shares outstanding
- 9.39M
- Short % of float
- 0.67%
- 50-day average
- 5.80
- 200-day average
- 8.47
Analyst view
Consensus: none
Price target (mean) 0.00
Next earnings
Consensus EPS estimate 0.00.
Financials — quick view
SER Revenue — quarterly 0
SER Net income — quarterly -6.36M
SER EPS — quarterly -0.55
About Serina Therapeutics, Inc.
Serina Therapeutics, Inc., a biotechnology company, develops drugs to treat neurological diseases and pain. Its lead product candidate is SER 252, a POZ conjugate for the treatment of Parkinson's disease. The company also develops SER 227 for long-acting pain relief; SER 214 to treat Parkinson's disease; and SER 228 for the treatment of epilepsy. In addition, it develops POZ technology in lipid nanoparticle delivered ribonucleic acid vaccines for infectious diseases. Serina Therapeutics, Inc. was founded in 2006 and is based in Huntsville, Alabama.
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- Website
- serinatherapeutics.com
News
- Custom Truck One Source, Inc. Reports Record Third Quarter 2026 Results and Increases Full Year 2026 Adjusted EBITDA and SER Revenue Guidance
- Seres Therapeutics to Present Preclinical Data for SER-428, an Investigational Live Biotherapeutic Designed to Reduce Risk of Bloodstream Infections in Critically Ill Patients, at IDWeek 2026
- Registration Is Now Open For Tribe Public's CEO Presentation and Q&A Webinar Event "A New Approach to Advanced Parkinson's Disease: Serina Discusses SER-252's Clinical Progress"
- Serina Therapeutics, Inc. (NYSEAMERICAN:SER) Sees Significant Decline in Short Interest
- Serina Therapeutics to Present at the H.C. Wainwright 28th Annual Global Investment Conference
- Serina Therapeutics Receives Recommendation From Independent Safety Monitoring Committee To Continue Its Phase 1b Registrational Trial Of SER-252 To Cohort 2
- Serina Therapeutics Reports Cohort 1 Observations from SER-252 Registrational Study in Advanced Parkinson's Disease and Advances to Cohort 2
- Serina Therapeutics Q2 EPS $(0.55) Misses $(0.47) Estimate, Sales $130.000K, Same YoY
- Serina Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Updates
- Serina Therapeutics to Participate in the BTIG Virtual Biotechnology Conference
Your note
Sign in to keep a note on SER — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| BAILEY GREGORY HUGH | Director | Purchase | Dec 16, 2024 | 67,243 |
| JUVENESCENCE LTD. | Beneficial Owner of more than 10% of a Class of Security | Stock Gift | Mar 13, 2023 | 16,447,500 |
| MINTZ STEVEN MICHAEL | Director | Purchase | Sep 11, 2024 | 0 |
| WEST MICHAEL D | Chief Executive Officer | Conversion of Exercise of derivative security | Mar 9, 2023 | 41,982 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Broadwood Capital, Inc. | 0.96% | 85,219 | 460.18K | Sep 29, 2024 |
| Waverly Advisors, LLC | 0.76% | 67,492 | 364.46K | Sep 29, 2024 |
| Vanguard Group Inc | 0.50% | 44,500 | 240.30K | Sep 29, 2024 |
| Geode Capital Management, LLC | 0.27% | 24,026 | 129.74K | Sep 29, 2024 |
| HighTower Advisors, LLC | 0.25% | 22,434 | 121.14K | Sep 29, 2024 |
| Millennium Management Llc | 0.22% | 19,256 | 103.98K | Sep 29, 2024 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Vanguard Total Stock Market Index Fund | 0.36% | 31,799 | 171.71K | Sep 29, 2024 |
| Fidelity Extended Market Index Fund | 0.18% | 15,593 | 84.20K | Oct 30, 2024 |
| Vanguard Extended Market Index Fund | 0.14% | 12,333 | 66.60K | Sep 29, 2024 |
| Northern Small Cap Core Fund | 0.09% | 7,900 | 42.66K | Sep 29, 2024 |
| Fidelity Series Total Market Index Fund | 0.04% | 3,720 | 20.09K | Oct 30, 2024 |
| Fidelity Total Market Index Fund | 0.03% | 2,592 | 14.00K | Oct 30, 2024 |